Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Combination of Lenalidomide and R-DHAP for Treatment of Relapsed and Refractory Aggressive B-NHL

Bertram Glass, MD, Anke Goerlitz, Sebastian Pfeiffer, Maike Nickelsen, MD, Andreas Huettmann, MD, Justin Hasenkamp, MD, Lorenz H. Truemper, MD PhD, Martin Dreyling, Michael G Kiehl, MD, Hans Salwender, MD, Norbert Schmitz, MD

Blood (2014) 124 (21): 1754.

https://doi.org/10.1182/blood.V124.21.1754.1754

Published: 2014

Journal Articles

Moderate Intensive Chemotherapy Including CNS-Prophylaxis with Liposomal Cytarabine Is Feasible and effective in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Trial From the German Multicenter Study Group for Adult ALL (GMALL)

Nicola Goekbuget, MD, Joachim Beck, MD, Monika Brueggemann, Thomas Burmeister, MD, Eike C. Buss, MD, Norbert Frickhofen, MD, Andreas Huettmann, MD, Anke Morgner, MD, Albrecht Reichle, Ingo Schmidt-Wolf, MD, Stefan Schwartz, MD, Hubert Serve, Prof. Dr. med., Bernd M Spriewald, MD, Michael Starck, MD, Matthias Stelljes, MD, Andreas Viardot, MD, Knut Wendelin, MD, Dieter Hoelzer, MD

Blood (2012) 120 (21): 1493.

https://doi.org/10.1182/blood.V120.21.1493.1493

Published: 2012

Journal Articles

Immunochemotherapy with Rituximab Improves Molecular CR Rate and Outcome In CD20+ B-Lineage Standard and High Risk Patients; Results of 263 CD20+ Patients Studied Prospectively In GMALL Study 07/2003

Dieter Hoelzer, MD, Andreas Huettmann, MD, Felix Kaul, Sebastian Irmer, Nadja Jaekel, Martin Mohren, Thomas Lipp, Knut Wedelin, Francisco de Valle, Mathias Schmid, MD, Eckhard Thiel, Prof., Dr., Dr., h.c., Monika Brueggemann, Michael Kneba, MD, PhD, Nicola Goekbuget, MD

Blood (2010) 116 (21): 170.

https://doi.org/10.1182/blood.V116.21.170.170

Published: 2010

Journal Articles

PEG-Asparaginase Intensification In Adult Acute Lymphoblastic Leukemia (ALL): Significant Improvement of Outcome with Moderate Increase of Liver Toxicity In the German Multicenter Study Group for Adult ALL (GMALL) Study 07/2003

Nicola Goekbuget, MD, Anja Baumann, MD, Joachim Beck, MD, Monika Brueggemann, MD, Helmut Diedrich, MD, Andreas Huettmann, MD, Lothar Leimer, MD, Stefan Zewen, MD, Martin Mohren, MD, Albrecht Reichle, MD, Markus Schaich, MD, Kerstin Schaefer-Eckart, MD, Marc Schmalzing, MD, Mathias Schmid, MD, Hubert Serve, MD, Reingard Stuhlmann, MD, Theis H Terwey, MD, Dieter Hoelzer, MD

Blood (2010) 116 (21): 494.

https://doi.org/10.1182/blood.V116.21.494.494

Published: 2010

Journal Articles

Long-Term Efficacy of the Terminal Complement Inhibitor Eculizumab in a Patient with Cold Agglutinin Disease (CAD)

Alexander Roeth, MD, Andreas Huettmann, MD, Ulrich Duehrsen, MD, Thomas Philipp, MD

Blood (2008) 112 (11): 2882.

https://doi.org/10.1182/blood.V112.11.2882.2882

Published: 2008

NARROW

Combination of Lenalidomide and R-DHAP for Treatment of Relapsed and Refractory Aggressive B-NHL

Moderate Intensive Chemotherapy Including CNS-Prophylaxis with Liposomal Cytarabine Is Feasible and effective in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Trial From the German Multicenter Study Group for Adult ALL (GMALL)

Immunochemotherapy with Rituximab Improves Molecular CR Rate and Outcome In CD20+ B-Lineage Standard and High Risk Patients; Results of 263 CD20+ Patients Studied Prospectively In GMALL Study 07/2003

PEG-Asparaginase Intensification In Adult Acute Lymphoblastic Leukemia (ALL): Significant Improvement of Outcome with Moderate Increase of Liver Toxicity In the German Multicenter Study Group for Adult ALL (GMALL) Study 07/2003

Long-Term Efficacy of the Terminal Complement Inhibitor Eculizumab in a Patient with Cold Agglutinin Disease (CAD)

Email alerts

ASH Publications

American Society of Hematology

Combination of Lenalidomide and R-DHAP for Treatment of Relapsed and Refractory Aggressive B-NHL

Moderate Intensive Chemotherapy Including CNS-Prophylaxis with Liposomal Cytarabine Is Feasible and effective in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Trial From the German Multicenter Study Group for Adult ALL (GMALL)

Immunochemotherapy with Rituximab Improves Molecular CR Rate and Outcome In CD20+ B-Lineage Standard and High Risk Patients; Results of 263 CD20+ Patients Studied Prospectively In GMALL Study 07/2003

PEG-Asparaginase Intensification In Adult Acute Lymphoblastic Leukemia (ALL): Significant Improvement of Outcome with Moderate Increase of Liver Toxicity In the German Multicenter Study Group for Adult ALL (GMALL) Study 07/2003

Long-Term Efficacy of the Terminal Complement Inhibitor Eculizumab in a Patient with Cold Agglutinin Disease (CAD)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only